Advertisement

Clinical and Experimental Medicine

, Volume 17, Issue 4, pp 541–546 | Cite as

New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients

  • Hanna Romanowicz
  • Dominik Strapagiel
  • Marcin Słomka
  • Marta Sobalska-Kwapis
  • Ewa Kępka
  • Anna Siewierska-Górska
  • Marek Zadrożny
  • Jan Bieńkiewicz
  • Beata Smolarz
Original Article

Abstract

Breast cancer is the most common cause of malignancy and mortality in women worldwide. This study aimed at localising homologous recombination repair (HR) genes and their chromosomal loci and correlating their nucleotide variants with susceptibility to breast cancer. In this study, authors analysed the association between single nucleotide polymorphisms (SNPs) in homologous recombination repair genes and the incidence of breast cancer in the population of Polish women. Blood samples from 94 breast cancer patients were analysed as test group. Individuals were recruited into the study at the Department of Oncological Surgery and Breast Diseases of the Institute of the Polish Mother’s Memorial Hospital in Lodz, Poland. Healthy controls (n = 500) were obtained from the Biobank Laboratory, Department of Molecular Biophysics, University of Lodz. Then, DNA of breast cancer patients was compared with one of the disease-free women. The test was supported by microarray analysis. Statistically significant correlations were identified between breast cancer and 3 not described previously SNPs of homologous recombination repair genes BRCA1 and BRCA2: rs59004709, rs4986852 and rs1799950. Further studies on larger groups are warranted to support the hypothesis of correlation between the abovementioned genetic variants and breast cancer risk.

Keywords

Breast cancer Polymorphisms Homologous recombination DNA repair Microarray analysis 

Notes

Acknowledgements

This study was supported by the Polish POIG Grant 01.01.02-10-005/08 TESTOPLEK from the European Regional Development Fund.

Funding

This work was supported by the Institute of Polish Mother’s Memorial Hospital, Lodz, Poland, from the Statutory Development Fund.

Authors’ contribution

D. S. and B. S. conceived and designed the experiments. M. S. K. and M. S performed the experiments—case group. H. R., B. S. and M. Z were involved in the case group design and collection. M. S. K, M. S., E. K. and A. S. G performed the experiments—control group. : M. S., M. S. K. and D.S analysed the case–control data. D. S contributed reagents/materials/analysis tools. B. S., H. R., D. S. and J. B contributed to the writing of manuscript. All authors approved the final manuscript.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All the study participants gave a informed written consent. A formal consent was also issued by the Bioethical Committee of the Institute of the Polish Mother’s Memorial Hospital in Lodz (Approval Number, 10/2012) and Review Board at the University of Lodz (Approval number 7/KBBN-UŁ/II/2014).

Human and animal rights

This study was supported by the Institute of Polish Mother’s Memorial Hospital, Lodz, Poland, from the Statutory Development Fund. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMedGoogle Scholar
  2. 2.
    Mimeault M, Batra SK. New promising drug targets in cancer- and metastasis-initiating cells. Drug Discov Today. 2010;15:354–64.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Aloyz R, Xu ZY, Bello V, et al. Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res. 2002;62:5457–62.PubMedGoogle Scholar
  4. 4.
    Liu C, Zhou S, Begum S, et al. Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer. Lung Cancer. 2007;55:303–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther. 2005;314:495–505.CrossRefPubMedGoogle Scholar
  6. 6.
    Ganguly A, Shields CL. Differential gene expression profile of retinoblastoma compared to normal retina. Mol Vis. 2010;16:1292–303.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Kauffmann A, Rosselli F, Lazar V, et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008;27:565–73.CrossRefPubMedGoogle Scholar
  8. 8.
    Sarasin A, Dessen P. DNA repair pathways and human metastatic malignant melanoma. Curr Mol Med. 2010;10:413–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Davidson JM, Gorringe KL, Chin SF, et al. Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer. 2006;83:1309–17.CrossRefGoogle Scholar
  10. 10.
    Forozan F, Mahlamaki EH, Monni O, et al. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res. 2000;60:4519–25.PubMedGoogle Scholar
  11. 11.
    Kytola S, Rummukainen J, Nordgren A, et al. Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer. 2000;28:308–17.CrossRefPubMedGoogle Scholar
  12. 12.
    Loveday RL, Greenman J, Simcox DL, et al. Genetic changes in breast cancer detected by comparative genomic hybridisation. Int J Cancer. 2000;86:494–500.CrossRefPubMedGoogle Scholar
  13. 13.
    Vijg J, Dolle MET. Large genome rearrangements as a primary cause of aging. Mech Ageing Dev. 2002;123:907–15.CrossRefPubMedGoogle Scholar
  14. 14.
    Bahar R, Hartmann CH, Rodriguez KA, et al. Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature. 2006;441:1011–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002;23:687–96.CrossRefPubMedGoogle Scholar
  16. 16.
    Helleday T. Pathways for mitotic homologous recombination in mammalian cells. Mutat Res. 2003;532:103–15.CrossRefPubMedGoogle Scholar
  17. 17.
    Silva SN, Tomar M, Paulo C, et al. Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51. Cancer Epidemiol. 2010;34:85–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA. XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res. 1999;59:2557–61.PubMedGoogle Scholar
  19. 19.
    Strapagiel D, Sobalska-Kwapis M, Słomka M, Marciniak B. Biobank Lodz—DNA based biobank at the University of Lodz, Poland, Open J Bioresour. 2016, in press.Google Scholar
  20. 20.
    Strapagiel D, Majewska M, Słomka M, Janik K, Sobalska M, Bartosz G. Method for determining sex, involves utilizing melting profile analysis technique, and obtaining specific fragments of DNA by PCR-based DNA from samples of human biological material. Patent Number(s): PL406569-A1, 2015.Google Scholar
  21. 21.
    Purcell S, Neale B, Todd-Brown K, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet. 2007;81:559–75.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Parshad R, Price FM, Bohr VA, Cowans KH, Zujewski JA, Sanford KK. Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Cancer. 1996;74:1–5.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomark Prev. 2003;12:689–98.Google Scholar
  24. 24.
    Xie H, Xia K, Rong H, Chen X. Genetic polymorphism in hOGG1 is associated with triple-negative breast cancer risk in Chinese Han women. Breast. 2013;22:707–12.CrossRefPubMedGoogle Scholar
  25. 25.
    Gross E, Meul C, Raab S, et al. Somatic copy number changes in DPYD are associated with lower risk of recurrence in triple-negative breast cancers. Br J Cancer. 2013;109:2347–55.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Smolarz B, Makowska M, Samulak D, et al. Single nucleotide polymorphisms (SNPs) of ERCC2, hOGG1, and XRCC1 DNA repair genes and the risk of triple-negative breast cancer in Polish women. Tumour Biol. 2014;35:3495–502.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Smolarz B, Zadrożny M, Duda-Szymańska J, et al. RAD51 genotype and triple-negative breast cancer (TNBC) risk in Polish women. Pol J Pathol. 2013;64:39–43.CrossRefPubMedGoogle Scholar
  28. 28.
    Kennedy RD, D’Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005;19:2925–40.CrossRefPubMedGoogle Scholar
  29. 29.
    San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229–57.CrossRefPubMedGoogle Scholar
  30. 30.
    Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett. 2005;219:125–35.CrossRefPubMedGoogle Scholar
  31. 31.
    Kadouri L, Kote-Jarai Z, Hubert A, et al. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer. 2004;90:2002–5.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hosseini M, Houshmand M, Ebrahimi A. RAD51 polymorphisms and breast cancer risk. Mol Biol Rep. 2013;40:665–8.CrossRefPubMedGoogle Scholar
  33. 33.
    Romanowicz-Makowska H, Smolarz B, Zadrozny M, et al. The association between polymorphisms of the RAD51-G135C, XRCC2-Arg188His and XRCC3-Thr241Met genes and clinico-pathologic features in breast cancer in Poland. Eur J Gynaecol Oncol. 2012;33:145–50.PubMedGoogle Scholar
  34. 34.
    Han J, Hankinson SE, Zhang SM. Interaction between genetic variations in DNA repair genes and plasma folate on breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:520–4.CrossRefPubMedGoogle Scholar
  35. 35.
    Costa S, Pinto D, Pereira D, et al. DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat. 2007;103:209–17.CrossRefPubMedGoogle Scholar
  36. 36.
    Sangrajrang S, Schmezer P, Burkholder I, et al. The XRCC3 Thr241Met polymorphism and breast cancer risk: a case control study in a Thai population. Biomarkers. 2007;12:523–32.CrossRefPubMedGoogle Scholar
  37. 37.
    Economopoulos KP, Sergentanis TN. XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;121:439–43.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res. 2005;3:531–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Parvin S, Islam MS, Al-Mamun MM, et al. Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population. Breast Cancer. 2016;. doi: 10.1007/s12282-016-0692.PubMedGoogle Scholar
  40. 40.
    Basu NN, Ingham S, Hodson J, et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Fam Cancer. 2015;14:531–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26:1291–9.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet. 2002;32:180–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4:665–76.CrossRefPubMedGoogle Scholar
  44. 44.
    Ledwoń JK, Hennig EE, Maryan N, et al. Common low-penetrance risk variants associated with breast cancer in Polish women. BMC Cancer. 2013;13:510.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Kluska A, Balabas A, Paziewska A, et al. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics. 2015;8:19.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Jakubowska A, Gronwald J, Menkiszak J, et al. The RAD51 135 G > C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev. 2007;16:270–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Jakubowska A, Gronwald J, Menkiszak J, et al. Hamann UBRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat. 2010;119:201–11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Hanna Romanowicz
    • 1
  • Dominik Strapagiel
    • 2
  • Marcin Słomka
    • 2
  • Marta Sobalska-Kwapis
    • 2
  • Ewa Kępka
    • 3
  • Anna Siewierska-Górska
    • 3
  • Marek Zadrożny
    • 4
  • Jan Bieńkiewicz
    • 5
  • Beata Smolarz
    • 1
  1. 1.Laboratory of Cancer Genetics, Department of Clinical PathomorphologyPolish Mother’s Memorial Hospital - Research InstituteLodzPoland
  2. 2.Biobank Lab, Department of Molecular Biophysics, Faculty of Biology and Environmental ProtectionUniversity of LodzLodzPoland
  3. 3.Department of Molecular Biophysics, Faculty of Biology and Environmental ProtectionUniversity of LodzLodzPoland
  4. 4.Department of Oncological Surgery and Breast DiseasesPolish Mother’s Memorial Hospital - Research InstituteLodzPoland
  5. 5.Department of Surgical, Endoscopic and Oncologic GynaecologyInstitute of Polish Mother’s Memorial HospitalLodzPoland

Personalised recommendations